Warning: count(): Parameter must be an array or an object that implements Countable in /home/logicben/public_html/drugtrialsformoney.com/wp-content/plugins/redux-framework/redux-core/inc/classes/class-redux-output.php on line 391

Evaluation of LY2606368 Therapy in Combination With Cyclophosphamide or Gemcitabine for Children and Adolescents With Refractory or Recurrent Group 3/Group 4 or SHH Medulloblastoma Brain Tumors

Evaluation of LY2606368 Therapy in Combination With Cyclophosphamide or Gemcitabine for Children and Adolescents With Refractory or Recurrent Group 3/Group 4 or SHH Medulloblastoma Brain Tumors
Conditions:   Brain Tumor;   Brain Tumor, Recurrent;   Brain Tumor, Refractory;   Brain Tumor, Pediatric;   Medulloblastoma;   Medulloblastoma Recurrent;   Medulloblastoma, Non-WNT/Non-SHH;   Medulloblastoma, Non-WNT/Non-SHH, Group 3;   Medulloblastoma, Non-WNT/Non-SHH, Group 4;   Brain Cancer;   CNS Cancer;   CNS Tumor;   CNS Neoplasm
Interventions:   Drug: Prexasertib;   Drug: Cyclophosphamide;   Drug: Gemcitabine;   Biological: filgrastim;   Biological: peg-filgrastim
Sponsors:   St. Jude Children’s Research Hospital;   Eli Lilly and Company
**RECRUITING NOW**

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

July 18, 2019 / by / in
Comments